The Aroon Indicator for ORMP entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator formed such a pattern. In 157 of the 186 cases the stock moved lower. This puts the odds of a downward move at 84%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
ORMP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ORMP crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORMP advanced for three days, in 216 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.540) is normal, around the industry mean (2.973). P/E Ratio (0.972) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.243) settles around the average of (128.121) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for TNGX turned positive on October 19, 2026. Looking at past instances where TNGX's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on TNGX as a result. In 74 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
TNGX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TNGX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +10.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNGX advanced for three days, in 246 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
TNGX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TNGX entered a downward trend on September 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.597) is normal, around the industry mean (2.973). P/E Ratio (-33.250) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (58.824) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TNGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ORMP | TNGX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 43 | |
SMR RATING 1..100 | 15 | 95 | |
PRICE GROWTH RATING 1..100 | 44 | 36 | |
P/E GROWTH RATING 1..100 | 93 | 42 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TNGX's Valuation (6) in the null industry is somewhat better than the same rating for ORMP (69) in the Pharmaceuticals Other industry. This means that TNGX’s stock grew somewhat faster than ORMP’s over the last 12 months.
TNGX's Profit vs Risk Rating (43) in the null industry is somewhat better than the same rating for ORMP (100) in the Pharmaceuticals Other industry. This means that TNGX’s stock grew somewhat faster than ORMP’s over the last 12 months.
ORMP's SMR Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for TNGX (95) in the null industry. This means that ORMP’s stock grew significantly faster than TNGX’s over the last 12 months.
TNGX's Price Growth Rating (36) in the null industry is in the same range as ORMP (44) in the Pharmaceuticals Other industry. This means that TNGX’s stock grew similarly to ORMP’s over the last 12 months.
TNGX's P/E Growth Rating (42) in the null industry is somewhat better than the same rating for ORMP (93) in the Pharmaceuticals Other industry. This means that TNGX’s stock grew somewhat faster than ORMP’s over the last 12 months.
| ORMP | TNGX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 74% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 80% | 1 day ago 82% |
| MACD ODDS (%) | N/A | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 86% |
| Advances ODDS (%) | 18 days ago 82% | 1 day ago 86% |
| Declines ODDS (%) | 1 day ago 81% | 9 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 73% |
| Aroon ODDS (%) | 1 day ago 84% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ORMP’s FA Score shows that 1 FA rating(s) are green while TNGX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ORMP’s TA Score shows that 4 TA indicator(s) are bullish while TNGX’s TA Score has 4 bullish TA indicator(s).
ORMP (@Biotechnology) experienced а -1.44% price change this week, while TNGX (@Biotechnology) price change was +21.59% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
ORMP is expected to report earnings on Nov 12, 2026.
TNGX is expected to report earnings on Nov 03, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, TNGX has been loosely correlated with AXON. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TNGX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To TNGX | 1D Price Change % | ||
|---|---|---|---|---|
| TNGX | 100% | +3.52% | ||
| AXON - TNGX | 41% Loosely correlated | +2.98% | ||
| IDYA - TNGX | 38% Loosely correlated | +1.83% | ||
| BNTC - TNGX | 36% Loosely correlated | +3.76% | ||
| ORMP - TNGX | 36% Loosely correlated | -0.48% | ||
| RCUS - TNGX | 35% Loosely correlated | +1.36% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TYA | 11.62 | 0.35 | +3.11% |
| Simplify Intermediate Term Treasury Futures Strategy ETF (TYA) | |||
| IHI | 54.87 | 1.45 | +2.71% |
| iShares U.S. Medical Devices ETF (IHI) | |||
| FEMV | 27.49 | 0.04 | +0.15% |
| Fidelity Enhanced Mid Cap Value ETF (FEMV) | |||
| EIM | 8.92 | 0.01 | +0.11% |
| Eaton Vance Municipal | |||
| HEQ | 11.32 | -0.10 | -0.88% |
| John Hancock Diversified Income Fund | |||